Close Menu

Advances in Spatial Genomics

A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.

The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January. 

BioSkryb will now have an exclusive global license for clinical applications of primary template directed amplification technology.

SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.

The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.